Acadia pharmaceuticals reports fourth quarter and full year 2022 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad), today announced its financial results for the fourth quarter and full year ended december 31, 2022. nuplazid® delivered net sales of $136.5 million in the fourth quarter of 2022 and $517.2 million for the full year. the improvement was mainly driven by an increase in demand in the long-term care channel and retention of continuing patients across all channels.
ACAD Ratings Summary
ACAD Quant Ranking